NovoCure Stock Plunges Amid Guidance Cut and CEO Transition

BTCC / BTCC Square / Global Cryptocurrency /

Author:

Release Time:

2025-07-29 22:41:02

BTCCSquare news:

Novo Nordisk shares plummeted 21% following a double blow of reduced financial guidance and leadership changes. The Danish pharmaceutical giant now projects full-year sales growth of 8%-14%, down sharply from previous estimates of 13%-21%. Operating profit forecasts were similarly slashed.

The guidance revision overshadowed the appointment of new CEO Mike Doustdar, set to begin August 7. Market skepticism prevailed despite board chairman Helge Lund's endorsement of Doustdar as the ideal leader for Novo's next growth phase.

Weaker U.S. sales of flagship drugs Wegovy and Ozempic drove the downward revision. While compounded drug competition previously pressured results, recent FDA restrictions on these alternatives may provide future relief.

By:

Log in to Reply

Palo Alto Networks Stock Dips Amid Acquisition Rumors

Articles on this site are sourced from public networks or curated by AI for informational purposes only and do not represent BTCC’s views. Original rights belong to the respective authors. For copyright concerns, please contact [email protected]. BTCC assumes no liability for the accuracy, timeliness, or completeness of this information, and disclaims all liability arising from reliance on such content. This content is for reference only and should not be taken as investment, legal, or commercial advice.